Long-term maralixibat treatment improves height in children with ALGS
Long-term treatment with maralixibat significantly increased height from baseline to week 204 in children with Alagille syndrome (ALGS), according to a poster presented at NASPGHAN 2022.
Data from patients who participated in the maralixibat clinical studies and the long-term open-label extensions were used to evaluate height and weight z-scores.
The greatest improvements in height and weight z-scores were found in patients who had the lowest scores at baseline. At week 48, patients that had the greatest catch-up weight gain also had the greatest catch-up height growth.
A greater accelerated height was also noted in patients who achieved a serum bile acid threshold <200 µmol/L. The authors suggest that this may mean bile acid homeostasis may facilitate improvement in height deficits.
Maralixibat Improves Growth in Patients with Alagille Syndrome: A 4-Year Analysis. Presented at: NASPGHAN 2022.
Official Media Partner & Publisher of ALGSA